🧾 What This Document Is

This is a Definitive Proxy Statement (DEF 14A) for Envista Holdings Corp (NVST). Think of it as a detailed invitation and report for the company's shareholders. It explains what will be voted on at the 2026 Annual Meeting and provides all the information shareholders need to make informed decisions. It's not about what happened in the past year (that's the annual report), but about who should lead the company and how its leaders are paid going forward.

🏢 What The Company Does

👉 In simple terms, Envista is a global dental products giant. They own over 30 trusted brands like Nobel Biocare (implants) and Ormco (braces). They sell everything from dental imaging machines and implants to braces and sterilization equipment to dentists in over 130 countries. It's a massive, behind-the-scenes player in your dental care.

🗳️ The Annual Meeting: What & When

Shareholders are invited to a virtual meeting on May 19, 2026, at 7:00 a.m. PT. They will vote on four key proposals:

Elect 8 directors to the Board (including CEO Paul Keel).
Ratify Ernst & Young LLP as the company's auditor for 2026.
Approve executive compensation (a "say-on-pay" advisory vote).
Choose how often to hold future say-on-pay votes (the Board recommends every year).

👉 Why it matters: This is how shareholders exercise their ownership rights. Voting "FOR" Proposal 3 approves the pay packages for top executives like the CEO.

💰 Financial Snapshot (2025 vs. 2024)

Envista showed a strong rebound in 2025:

Revenue: Grew to $2.72 billion (up 8.3% from $2.51B).
Profitability: Swung to a $47 million net income from a $1.12 billion net loss in 2024.
Cash Flow: Generated $275.7 million from operations.
Key Metric (Adj. EBITDA): Rose to $371.7 million (a 13.7% margin).

👉 Why it matters: The company returned to growth and profitability after a tough 2024, which is a positive signal for investors.

👥 Meet the Leadership & Board

The document details the people running the show.

CEO: Paul Keel (age 56), who joined in 2024. He received a large "make-whole" stock award of 860,770 shares (combining two grants) to compensate for awards he left behind at his previous job.
Board of Directors: 8 nominees are proposed, led by independent Chairman Scott Huennekens. The board is highlighted for its independence (7 of 8 are independent) and deep experience in medical technology, finance, and governance.
Top Shareholders: Major investment firms like The Vanguard Group (10.5%), BlackRock (9.7%), and Ariel Investments (7.0%) are the biggest owners.

📊 Executive Compensation Deep Dive

This is the core of the "say-on-pay" vote. Here's how top executives are paid:

Base Salary: Stable cash income.
Annual Cash Bonus: Based on yearly goals like sales growth and profit.
Long-Term Incentives (Stock): The biggest chunk. Awards are a mix of:
- Performance Stock Units (PSUs): Tied to 3-year financial goals.
- Stock Options & RSUs: Tied to the stock price rising.
Specific 2025 Grants: The filing lists exact stock awards to executives. For example, the former CEO Amir Aghdaei received a grant of 113,370 PSUs in February 2024. These awards had a "fair value" of $9.70 each at grant.

👉 Why it matters: This structure is designed to tie executive pay directly to company performance and stock price, aligning their interests with shareholders.

🏛️ Corporate Governance Highlights

Envista emphasizes strong governance practices:

Annual Director Elections: No staggering boards.
Separate Chair & CEO: An independent chairman leads the board.
Strong Committees: All members of the key Audit, Compensation, and Nominating committees are independent directors.
No "Poison Pill": The company has no shareholder rights plan that could hinder takeovers.
Sustainability Oversight: The board's Nominating & Governance Committee oversees the company's ESG (Environmental, Social, Governance) strategy.

⚖️ Strengths & Risks (Big Picture)

👍 Strengths: Strong brand portfolio, return to growth, solid governance, and compensation tied to performance. The board has deep MedTech experience.
⚠️ Risks: The dental industry is competitive and sensitive to economic cycles. The company must successfully execute its strategy to maintain growth. A large portion of executive pay is "at-risk" (stock-based), which depends on future performance.

🧠 The Analogy

This proxy statement is like the annual report card and family meeting for a business. The "students" (management) present their report card (the financials), the "parents" (shareholders) get to grade them (the votes), and they also vote on the rules and allowances for the next year (director elections and pay plans). It's all about transparency and accountability.

🧩 Final Takeaway

Envista is presenting a story of recovery and alignment. After a rocky 2024, it posted solid 2025 results and is asking shareholders to approve its leadership and a pay plan designed to reward executives for continuing that upward trend. The vote is a chance for owners to endorse or reject the current direction.

Envista Holdings Corp — DEF 14A Filing